Comparative study on transcatheter arterial chemoembolization, portal vein embolization and high intensity focused ultrasound sequential therapy for patients
| Autor: | Jian-Jun Liu, Lin Cui, Xin-En Huang, Xiang-Rong Zhou, Xue-Jun He, Xing-Xiang Liu, Xing-Jun Wu, Yong Jiang |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Carcinoma Hepatocellular Epidemiology Nausea medicine.medical_treatment Urology medicine Humans Chemoembolization Therapeutic Transcatheter arterial chemoembolization Ultrasound High-Intensity Focused Transrectal Aged business.industry Portal Vein Significant difference Liver Neoplasms Public Health Environmental and Occupational Health Arteries Middle Aged medicine.disease High-intensity focused ultrasound Surgery Survival Rate Treatment Outcome Oncology Hepatocellular carcinoma Portal vein embolization Every Two Months Vomiting Female medicine.symptom business |
| Zdroj: | Asian Pacific journal of cancer prevention : APJCP. 13(12) |
| ISSN: | 2476-762X |
| Popis: | Objective: To investigate the safety and efficacy of transcatheter arterial chemoembolization (TACE), combined with portal vein embolization (PVE), and high intensity focused ultrasound (HIFU) sequential therapy in treating patients with hepatocellular carcinoma (HCC). Methods: Patients with inoperative HCC were treated by two methods: in the study group with TACE first, then PVE a week later, and then TACE+PVE every two months as a cycle, after 2~3 cycles finally HIFU was given; in the control group only TACE+PVE was given. Response (CR+PR), and disease control rate (CR+PR+SD), side effects, overall survival and time to progress were calculated. Results: Main side effects of both groups were nausea and vomiting. No treatment related death occurred. In the study group, 32 patients received TACE for overall 67 times, PVE 64 times, and HIFU 99 times; on average 2.1, 2 and 3.1 times for each patient, respectively. In the control group, 36 patients were given TACE 78 times and PVE 74 times, averaging 2.2 and 2.1 times per patient. Effective rate: 25.0% in study group and 8.3% in control group (p>0.05). Disease control rates were 71.9% and 44.4%, respectively (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|